Section Arrow
GNPX.NASDAQ
- Genprex
(Financial Status)
Quotes are at least 15-min delayed:2025/01/12 05:54 EST
Last
 0.78
+0.0089 (+1.15%)
Day High 
0.79 
Prev. Close
0.7711 
1-M High
1.26 
Volume 
249.32K 
Bid
0.7647
Ask
0.79
Day Low
0.76 
Open
0.79 
1-M Low
0.7601 
Market Cap 
6.56M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.86 
20-SMA 0.93 
50-SMA 1.28 
52-W High 13 
52-W Low 0.2806 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-10.69/-1.15
Enterprise Value
6.56M
Balance Sheet
Book Value Per Share
0.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/12 05:54 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for largepatient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.